Idorsia Ltd (XSWX:IDIA)

CHF 2.27 0.146 (6.87%) Market Cap: 408.69 Mil Enterprise Value: 1.43 Bil PE Ratio: 16.34 PB Ratio: 0 GF Score: 52/100

Half Year 2024 Idorsia Ltd Earnings Call Transcript
Jul 25, 2024

CHF2.74 (+18.17%)

Earnings
Idorsia Ltd to Discuss the TRYVIO FDA Approval Transcript
Mar 20, 2024
Idorsia Ltd at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q3 2023 Idorsia Ltd Earnings Call Transcript
Oct 24, 2023

CHF1.62 (-13.10%)

Earnings
Half Year 2023 Idorsia Ltd Earnings Call Transcript
Jul 25, 2023

CHF6.43 (-5.72%)

Earnings
Sosei Group Corp to Acquire Idorsia Ltd Pharmaceuticals Business in Japan and APAC Transcript
Jul 20, 2023
Q1 2023 Idorsia Ltd Earnings Call Transcript
Apr 25, 2023

CHF8.99 (-6.98%)

Earnings
Full Year 2022 Idorsia Ltd Earnings Call Transcript
Feb 07, 2023

CHF12.51 (-8.89%)

Earnings
Idorsia Ltd at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Idorsia Ltd Cenerimod Phase 3 Initiation Webcast Transcript
Dec 15, 2022
Idorsia Ltd Conference Call Transcript
Nov 08, 2022
Q3 2022 Idorsia Ltd Earnings Call Transcript
Oct 25, 2022

CHF13.95 (+3.95%)

Earnings
Half Year 2022 Idorsia Ltd Earnings Call Transcript
Jul 26, 2022

CHF11.42 (+0.62%)

Earnings
Idorsia Ltd To Discuss PRECISION top-line results Transcript
May 24, 2022
Full Year 2021 Idorsia Ltd Earnings Call Transcript
Feb 08, 2022

CHF19.88 (-4.70%)

Earnings
Idorsia Ltd To Discuss Daridorexant Phase 3 program published in The Lancet Neurology Call Transcript
Jan 20, 2022
Idorsia Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Half Year 2021 Idorsia Ltd Earnings Call Transcript
Jul 27, 2021

CHF24.6 (-1.99%)

Earnings
Idorsia Ltd To Discuss Phase 3 Program -Corporate Call Transcript
Jun 28, 2021
Idorsia Ltd - Pre Recorded Special Call Transcript
Mar 10, 2021
Full Year 2020 Idorsia Ltd Earnings Call Transcript
Feb 04, 2021

CHF26.68 (-1.11%)

Earnings
Idorsia Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Half Year 2020 Idorsia Ltd Earnings Call Transcript
Jul 23, 2020

CHF26.6 (+0.23%)

Earnings
Idorsia Ltd - Special Call Transcript
Jul 06, 2020
Idorsia Ltd - Special Call Transcript
Apr 20, 2020
Full Year 2019 Idorsia Ltd Earnings Call Transcript
Feb 06, 2020

CHF32.23 (-1.26%)

Earnings
Half Year 2019 Idorsia Ltd Earnings Call Transcript
Jul 23, 2019

CHF21.39 (-7.52%)

Earnings

Idorsia Ltd To Discuss Daridorexant Phase 3 program published in The Lancet Neurology Call Transcript

Jan 20, 2022 / 01:00PM GMT

Release Date Price: CHF22.04 (+4.55%)

Transcript

Operator

Good day and thank you for standing by. Welcome to the daridorexant Phase III program published in The Lancet Neurology Conference Call. (Operator Instructions)

I must advise you that this conference call is being recorded today, Thursday, the 20th of January 2022. I would now like to hand over to your speaker for today, Mr. Andrew Weiss. Please go ahead, sir.

Andrew C. Weiss

Idorsia Ltd - Senior VP and Head of IR & Corporate Communications

Thank you, operator. Good morning, good afternoon, everyone. This is Andrew speaking, Investor Relations at Idorsia. We're here to have a webcast to discuss the newly published results of daridorexant in the Lancet Neurology publication that was made available this morning.

With me on the call today are our CEO, Jean-Paul Clozel; our Chief Scientific Officer, Martine Clozel; our Head of Global Clinical Development, Guy Braunstein. And joining us afterwards for the Q&A, we will also have Simon Jose. Next slide.

As customary, we will be making forward-looking statements during this webcast

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.